Oxytocin
Endogenous nonapeptide
- Injection
- Oral
- Nasal spray
- Suppository
- Gel or cream
Injection · Nasal spray · Gel or cream — usually daily, or before a specific occasion.
Available · from about $199/mo
Oxytocin is a nine-amino-acid hormone your body already makes. It is synthesized in the hypothalamus, stored in and released from the posterior pituitary, and it goes out during labor, breastfeeding, sexual activity and warm physical contact. It acts on a single receptor, OXTR, which sits in the uterus and mammary glands and also in the amygdala, nucleus accumbens, hippocampus and prefrontal cortex — the reason a labor drug ended up in a conversation about relationships.
What it does centrally is narrower than the popular version. The best current description is a salience modulator: threat reactivity in the amygdala goes down, the circuits handling social sensory information sharpen, and dopaminergic reward signaling amplifies. That is a change in what the brain attends to, not a mood effect and not a trust switch.
The 2005 result that put oxytocin on magazine covers did not replicate. What replaced it is smaller, stranger and more honest.
The replication story is the thing to carry away. A widely cited 2005 trust-game finding failed to hold up in registered trials. Then the largest controlled test of the social hypothesis — 290 patients, twenty-four weeks, autism — found no difference from placebo on its primary social-interaction measure. What survives is the brain-imaging work and a subgroup signal in high-acuity PTSD, now being tested at UCSD. Underneath all of it sits an unresolved delivery question: nobody has directly measured how much of an intranasal dose reaches central receptors in a human being. For the study-by-study record and the delivery debate in full, read the deep-dive on PeptideWellness.
Who it's for (or who should avoid)
What it's aimed at
Oxytocin is prescribed off-label for goals the evidence supports unevenly, so it is worth separating them:
- Intimacy and presence — the most common reason people ask for it, and the one with the least controlled support; the plausible mechanism is the salience effect rather than desire itself
- Social discomfort — studied extensively, with the large registered trials mostly negative on primary endpoints
- Stress reactivity — the amygdala findings are the strongest part of the mechanistic case, and they are measurements of brain activity rather than of how a week goes
- Post-trauma work, as an adjunct to therapy — the one place a real subgroup signal exists, in high-acuity trauma survivors, and where a trial is running now
- Obstetric use — the approved indication, by injection, in a hospital, and not what anything else on this page is about
It is an adjunct to the actual work — therapy, relationship work, deliberate social practice — and the honest framing is that the compound is being tested on the question, not that it has answered it.
Who should avoid it
- Anyone pregnant or breastfeeding — the injectable form is a labor drug, which is precisely why intranasal use in pregnancy is not something to improvise; no controlled trials cover it
- People with a history of cardiovascular events — high-dose injectable oxytocin affects blood pressure and heart rate, and the interaction at intranasal doses is not well characterized
- Anyone on several CNS-active medications — oxytocin acts on stress and reward systems, so SSRIs, benzodiazepines and similar belong in the conversation with your prescriber
- Anyone considering indefinite daily use — controlled safety data runs to about six months and no further
- Anyone offered oxytocin acetate — it has no USP monograph, it is not a permissible compounding form, and its presence on a label tells you where the product came from
Route, dose and course
Intranasally, in most of the research: 24 to 40 IU a day, split across two or three administrations, sometimes prescribed for use before a specific occasion rather than on a daily schedule. Some providers write a sublingual formulation instead. Cycling — a few weeks on, a week or two off — is a common pattern, used to check what baseline feels like rather than because tolerance has been demonstrated.
Two things about the route are worth more attention than the number:
- The delivery question is unresolved — how much of a nasal dose reaches central receptors has never been directly measured in a person, so a protocol specified to the IU is more precise than the underlying science
- The available product is a different route — the only oxytocin price published by a provider we cover is for a topical cream, and the human evidence base is intranasal; those are not interchangeable
- The permissible form is oxytocin USP — it compounds legally as a component of an approved drug with a monograph, which is why this compound does not depend on the Bulks List
- Reconstituted product is perishable — compounded oxytocin is dispensed with a short dating window, and storage instructions on the label are not optional advice
The usual arc
Read this first. There is no reliable response curve to draw here, and drawing one would be the dishonest part. What the windows below track is what the trials measured and when they stopped — including the large one that measured for twenty-four weeks and found nothing on its primary endpoint.
There is no honest response curve for the off-label uses, so the arc below tracks the research instead: what was measured, over how long, and where it stopped.
- SINGLE DOSEWhere almost all the data isMost of the human literature is one dose, one session, one scan or one behavioral task. That is where the amygdala and reward-circuit findings come from, and it is a real result about brain activity rather than about how anyone feels in a month.
- WEEK 24Where the big trial endedThe largest controlled test — 290 patients, twenty-four weeks, autism — found no difference from placebo on its primary social-interaction measure. Any claim about sustained social benefit has to get past that study first.
- STILL OPENThe PTSD questionA subgroup signal in high-acuity trauma survivors is the one live lead, and a trial at UCSD is testing it now. Nobody knows the answer yet, which is a better description of this compound than any timeline of expected effects.
Available · from about $199/mo
Every headline price in this market excludes something. These are normalized to a calendar month, cheapest first, with the exclusion spelled out — the published figure is the footnote under it.
| Provider | From, per month | What that figure excludes | Coverage |
|---|---|---|---|
| MaximusMen's hormone focus | $199read 2026-08-13 | The $99 applies to the first month only. | Not published |
Will it work where you live?
A coverage claim here is all-fifty-states or nothing — it never separates one state from another — so we can't filter this list by state without inventing the fact that would make the filter true. What we can tell you is which state-level rules decide access: telehealth rules, non-resident pharmacy licensing, and who is allowed to prescribe.
Prices move. We re-read them.
Questions we get about Oxytocin
Is oxytocin FDA-approved?
Yes, and for something other than what most people are reading about. Injectable oxytocin — Pitocin — is approved for obstetric use: inducing labor, controlling postpartum bleeding, and related indications. There is no FDA-approved intranasal or topical oxytocin product for bonding, intimacy or stress. Those uses are off-label, written by licensed clinicians and prepared by compounding pharmacies.
Does it actually work?
For the obstetric indications, yes, and it has for decades. For the social and emotional ones, the honest answer is that the field has had a hard few years. The 2005 trust-game result that put oxytocin on magazine covers failed to replicate in registered trials. A 290-patient, twenty-four-week autism trial found no difference from placebo on its primary social-interaction measure. What survives is narrower and more interesting: reproducible changes in how the brain processes social and threat cues, and a subgroup signal in high-acuity PTSD that is being tested properly right now.
Is it legal to get compounded?
Yes, and its legal footing is better than most compounds on this site. A pharmacy can prepare it because oxytocin is a component of an approved drug and has a USP monograph, which is its own pathway under 503A and 503B — it does not need to appear on the Bulks List at all. One distinction matters when you read a label: oxytocin USP is the permissible form, while oxytocin acetate, which turns up from research-chemical sellers, has no monograph and is not.
See what licensed providers actually carry →Does the nasal spray reach the brain?
Nobody has directly measured it in a person, and this is the load-bearing uncertainty under the whole intranasal literature. Cerebrospinal-fluid studies suggest a small fraction of an intranasal dose reaches central receptors. That is enough for an effect to be plausible and not enough to explain the size of the effects that get claimed — and it is a reason to read any protocol built on precise nasal dosing with some skepticism about the precision.
Are there side effects?
In the published intranasal trials they are mild and mostly local: headache, nasal irritation, occasional nausea. One trial reported transient gynecomastia in a male participant. The more useful caveat is the length of the record rather than its contents — safety beyond about six months has not been studied in controlled trials, and daily indefinite use is outside what anyone has measured.
How much does it cost?
Most providers quote compounded oxytocin inside the intake rather than publishing a figure. One on our list publishes: Maximus's oxytocin calming cream runs $99 for the first month and $199 a month after that, read off their own product page on August 13, 2026. Note what that buys — a topical cream, not the intranasal spray the research used. Insurance does not cover compounded oxytocin in either form.
How the bill breaks downWe publish no medical reviewer by design. Every claim on this page traces to a source we hold on file, and the reviewed write-up with those citations lives on our hub. Read the full research on PeptideWellness ↗
Fuel your protocol with
the latest research + reviews
Independent updates on peptide therapy, breaking news from compounding pharmacies, and exclusive guides — straight to your inbox.
